In case PRCA is diagnosed, therapy with Aranesp must be discontinued and patients should not be switched to another recombinant erythropoietic protein (see section 4.4).
165 Aranesp y los pacientes no se deben cambiar a ninguna otra proteína estimulante de la eritropoyesis (ver sección 4.4).